OverviewSuggest Edit

Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
TypePublic
Founded2013
HQCambridge, MA, US
Websiteeditasmedicine.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Feb 2020)208(+17%)
Job Openings34
Revenue (FY, 2020)$90.7 M(+342%)
Share Price (Jun 2021)$33.7
Cybersecurity ratingCMore

Key People/Management at Editas Medicine

Cynthia Collins

Cynthia Collins

President, Chief Executive Officer & Director
James C. Mullen

James C. Mullen

Chairman, President, and Chief Executive Officer
David Litvak

David Litvak

Associate Director, Technical Operations
Harry Gill

Harry Gill

Senior Vice President, Operations
Gad Berdugo

Gad Berdugo

Chief Business Officer
Lisa A. Michaels

Lisa A. Michaels

Executive Vice President and Chief Medical Officer
Show more

Editas Medicine Office Locations

Editas Medicine has offices in Cambridge and Boulder
Cambridge, MA, US (HQ)
300 Third St
Boulder, CO, US
4909 Nautilus Ct N Suite 208/211
Cambridge, MA, US
11 Hurley St
Show all (3)

Editas Medicine Financials and Metrics

Editas Medicine Revenue

Editas Medicine's revenue was reported to be $90.73 m in FY, 2020
USD

Revenue (Q1, 2021)

6.5m

Net income (Q1, 2021)

(56.7m)

EBIT (Q1, 2021)

(56.9m)

Market capitalization (4-Jun-2021)

2.3b

Closing stock price (4-Jun-2021)

33.7

Cash (31-Mar-2021)

354.9m

EV

1.9b
Editas Medicine's current market capitalization is $2.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.1m13.7m31.9m20.5m90.7m

General and administrative expense

46.3m50.5m55.0m64.6m67.6m

R&D expense

57.0m83.2m90.7m96.9m158.0m

Operating expense total

103.2m133.7m145.7m161.5m225.6m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

185.3m146.6m134.8m238.2m139.7m

Accounts Receivable

88.0k679.0k30.0k418.0k6.0m

Prepaid Expenses

2.4m5.8m6.3m10.9m

Inventories

1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(97.2m)(120.3m)(110.0m)(133.7m)(116.0m)

Depreciation and Amortization

2.7m3.3m4.0m

Inventories

1.8m

Accounts Payable

4.6m(1.5m)1.8m274.0k855.0k
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Editas Medicine Operating Metrics

FY, 2016

Patents Issued

41

Patents Pending

500
Show all operating metrics

Editas Medicine Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Editas Medicine Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Editas Medicine Online and Social Media Presence

Embed Graph

Editas Medicine News and Updates

Editas Medicine Announces First Quarter 2021 Results and Update

Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2…

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting

Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Cindy Collins to Step Down Effective February 15, 2021 Cindy Collins to Step Down Effective February 15, 2021

Can Editas Medicine Stock Bounce Back After A 13% Drop In 5 Days ?

Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to issue 3.5 million shares at $66 per share. The selling pressure can be attributed to the fact that the...
Show more

Editas Medicine Frequently Asked Questions

  • When was Editas Medicine founded?

    Editas Medicine was founded in 2013.

  • Who are Editas Medicine key executives?

    Editas Medicine's key executives are Cynthia Collins, James C. Mullen and David Litvak.

  • How many employees does Editas Medicine have?

    Editas Medicine has 208 employees.

  • What is Editas Medicine revenue?

    Latest Editas Medicine annual revenue is $90.7 m.

  • What is Editas Medicine revenue per employee?

    Latest Editas Medicine revenue per employee is $436.2 k.

  • Who are Editas Medicine competitors?

    Competitors of Editas Medicine include Biocytogen, Explora Biotech and Tierra Biosciences.

  • Where is Editas Medicine headquarters?

    Editas Medicine headquarters is located at 300 Third St, Cambridge.

  • Where are Editas Medicine offices?

    Editas Medicine has offices in Cambridge and Boulder.

  • How many offices does Editas Medicine have?

    Editas Medicine has 3 offices.